Virpax Pharmaceuticals Announces Public Offering Pricing to Fuel Drug Development and Innovation
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a forward-thinking preclinical-stage pharmaceutical company specializing in groundbreaking drug delivery systems for pain management, has unveiled the pricing details of its latest public offering. The offering includes shares of the company’s common stock priced at $0.20 per share, alongside pre-funded warrants available at $0.19999 per share (after a $0.00001 deduction per warrant). This strategic move aims to accelerate the company’s mission to revolutionize pain management through innovative, non-opioid solutions.
The funds raised from this offering will primarily support Virpax’s research and development initiatives, with a significant focus on advancing its lead product candidate, Probudur, into clinical trials. Additionally, the proceeds will be allocated toward marketing and advertising efforts to bolster the company’s presence in the financial sector, as well as to cover working capital and other general corporate expenses.
Strategic Fundraising with Spartan Capital Securities
Spartan Capital Securities, LLC, a prominent financial services firm, has been appointed as the exclusive placement agent for this offering. Their expertise ensures a seamless and efficient fundraising process, enabling Virpax to secure the necessary capital to drive its ambitious goals.
The public offering is slated to close on January 29, 2025, pending the fulfillment of standard closing conditions. This offering is being conducted under Virpax’s Form S-1 registration statement (File No. 333-284089), initially filed with the Securities and Exchange Commission (SEC) on December 30, 2024. The statement underwent amendments on January 15 and January 17, 2025, before receiving final SEC approval on January 27, 2025.
Accessing the Prospectus
Interested investors can review the final prospectus related to this offering on the SEC’s official website at www.sec.gov. Alternatively, copies of the prospectus can be obtained from Spartan Capital Securities, LLC, located at 45 Broadway, 19th Floor, New York, NY 10006, once they become available.
Legal Disclaimer
It’s important to note that this announcement does not constitute an offer to sell or a solicitation to buy any securities. Furthermore, no securities will be sold in jurisdictions where such an offer or sale would be unlawful without proper registration or qualification under local securities laws.
About Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc. is at the forefront of developing advanced, proprietary drug delivery systems designed to address a wide range of pain-related conditions. By focusing on non-opioid and non-addictive solutions, the company is committed to providing safer and more effective treatments for pain management and central nervous system disorders. Leveraging cutting-edge drug-releasing technologies, Virpax aims to improve patient compliance and enhance overall quality of life.
A Commitment to Innovation in Pain Management
Virpax’s dedication to innovation is evident in its robust pipeline of product candidates, which aim to address unmet needs in pain management. The company’s focus on non-addictive alternatives is particularly timely, given the ongoing opioid crisis and the urgent need for safer pain relief options. By advancing its lead candidate, Probudur, Virpax is taking a significant step toward delivering transformative solutions to patients worldwide.
Investing in the Future of Healthcare
This public offering represents a pivotal moment for Virpax Pharmaceuticals as it seeks to secure the resources needed to bring its innovative treatments to market. The funds raised will not only support clinical trials but also enable the company to expand its reach and impact within the pharmaceutical and financial sectors. Investors have the opportunity to contribute to a company that is poised to make a meaningful difference in the lives of patients suffering from chronic pain and related conditions.
Join Virpax on Its Journey
For more information about Virpax Pharmaceuticals and its innovative pipeline of treatments, visit www.virpaxpharma.com. Virpax’s common stock is listed on the Nasdaq Capital Market under the ticker symbol VRPX, offering investors a chance to be part of a company dedicated to redefining pain management through science and innovation.
By supporting Virpax Pharmaceuticals, investors are not only contributing to the growth of a promising pharmaceutical company but also playing a role in addressing one of the most pressing healthcare challenges of our time. With its commitment to innovation and patient-centric solutions, Virpax is well-positioned to make a lasting impact in the field of pain management.
